Health condition
Liquid biopsy monitoring
Liquid biopsy analyses fragments of tumour DNA circulating in blood, enabling mutation profiling without surgery and increasingly sensitive tracking of residual disease and relapse; it is entering routine UK practice for selected cancers while wider uses mature in trials.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.
-
Circulating tumour DNA (ctDNA) can identify targetable mutations when tissue is scarce
-
Established uses include EGFR testing in lung cancer and resistance tracking on targeted therapy
-
Molecular residual disease (MRD) assays can flag relapse months before scans - trials are defining what to do with that lead time
-
A negative liquid biopsy does not exclude cancer; tissue remains the reference standard
Understanding the condition
What it is and what happens next.
What causes it, how it is diagnosed, and the treatment routes available in the UK.
What it is and how it feels
Dying tumour cells shed DNA into the bloodstream, and modern sequencing reads those fragments against the noise of normal DNA - turning a blood draw into a window on the cancer’s genetics. Where biopsy is hazardous or tissue exhausted, plasma profiling already guides drug choice in lung and breast cancer; on targeted therapy, serial samples watch resistance mutations emerge and prompt a switch before clinical progression declares itself.
Diagnosis and treatment routes
The frontier is minimal residual disease: after curative surgery, tumour-informed ctDNA assays detect relapse with a lead time of months, and studies in bowel and other cancers are testing whether acting on that signal - escalating or sparing chemotherapy - improves outcomes rather than merely lengthening anxiety. Sensible use therefore separates today’s validated roles from tomorrow’s: worth asking your oncologist whether ctDNA testing is informative for your tumour type now, available via the NHS Genomic Medicine Service, privately, or within a trial. If you are waiting for results or want a second opinion on a proposed plan, a private consultation with a specialist who treats this condition regularly can usually be arranged quickly, and most will review your existing scans, biopsy reports and MDT correspondence.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a consultant oncologist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.
Frequently asked
Common questions about Liquid biopsy monitoring.
Quick, plain-English answers to what people ask us most.
-
What is liquid biopsy monitoring?
Liquid biopsy monitoring is a blood test that detects small fragments of tumour DNA circulating in the bloodstream, allowing cancer to be monitored without the need for repeated tissue biopsies. It's increasingly used to track treatment response and detect cancer recurrence earlier.
-
How does liquid biopsy work?
It works by detecting circulating tumour DNA or cells that are shed from cancer tumours into the bloodstream, which can be analysed for specific genetic mutations relevant to diagnosis, treatment selection, or monitoring for recurrence. Highly sensitive laboratory techniques are needed to detect these small amounts of genetic material.
-
What is liquid biopsy used for?
It's used for several purposes including identifying specific genetic mutations to guide targeted cancer treatment, monitoring how well a cancer is responding to treatment, and detecting early signs of cancer recurrence, sometimes before it would be visible on standard imaging. Its use continues to expand as the technology develops.
-
Is liquid biopsy as reliable as a traditional tissue biopsy?
It's a valuable complementary tool but isn't always a complete replacement for tissue biopsy, as sensitivity can vary depending on cancer type and stage, and a negative result doesn't completely rule out cancer. Your oncologist will interpret results alongside other tests, including imaging and, where needed, tissue sampling.
-
What are the benefits of liquid biopsy over traditional biopsy?
It's minimally invasive, requiring only a blood sample rather than a surgical or needle biopsy procedure, and can be repeated relatively easily over time to track changes in the cancer's genetic profile. This makes it particularly useful for ongoing monitoring throughout treatment.
-
How is liquid biopsy performed?
It's performed with a simple blood draw, similar to routine blood tests, which is then sent to a specialised laboratory for detailed genetic analysis. No special preparation is usually needed beforehand.
-
How often is liquid biopsy monitoring repeated?
This depends on your specific cancer type and treatment plan, but it's often used at key points such as before starting treatment, during treatment to check response, and periodically afterwards to monitor for recurrence. Your oncology team will determine the appropriate monitoring schedule for your situation.
-
Liquid biopsy vs tissue biopsy — what's the difference?
Tissue biopsy involves physically removing a sample of tumour tissue, providing detailed structural information but requiring an invasive procedure, while liquid biopsy analyses tumour genetic material from a blood sample, offering a less invasive but sometimes less comprehensive picture. The two are often used together to provide complementary information.
-
Is liquid biopsy available for all cancer types?
Its use and reliability vary by cancer type, with some cancers being more thoroughly studied and validated for this technology than others. Your oncologist can advise whether it's an appropriate and validated option for your specific cancer.
-
When should I discuss liquid biopsy monitoring with my specialist, and how quickly can I be seen privately?
If you're undergoing cancer treatment and want to discuss whether liquid biopsy monitoring is appropriate for your situation, raise this with your oncology team. Private oncology consultations for this discussion can typically be arranged within about two weeks.